Astellas Pharma China, Inc.

Quick facts

Marketed products

• Mycophenolic acid drugs
• Perdipine injection
• Tacrolimus immediate-release formulation · Immunology
  Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses.
• Tacrolimus prolonged-release formulation · Immunology
  Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing immune rejection.
• Tacrolimus sustained-release capsule · Immunology
  Tacrolimus inhibits calcineurin phosphatase, suppressing T-cell activation and proliferation to prevent organ rejection and treat autoimmune conditions.

Phase 3 pipeline

• Cyclophosphamide injections · Oncology
  Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.
• Plaebo · Other

Phase 2 pipeline

• ATF-Fresenius S · Immunology
  ATF-Fresenius S is a drug that works by modulating the immune system.

Phase 1 pipeline

• Tamsulosin formulation-A
• Tamsulosin formulation-B

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Astellas Pharma China, Inc. portfolio CI brief
• Astellas Pharma China, Inc. pipeline updates RSS